ArchiveAugust 2012

Team G: Maria’s leaving us today

Today is Maria Espasandin’s last day in our group! She has worked as our clinical research manager for over 10 years. Dependable, thorough, highly-skilled and an asset we are can’t afford to be losing. Ask Maria to get a trial or study protocol written and through ethics and bingo it is done. Maria was also the person responsible for arranging our annual research days...

Team G News: Leaving us


Bye Bye Beki from Shift MS, who is moving on to pastures new.

Nurse Maria Espasandin Research Manager has also jumped Ship to work with the Enemy (🙂) ..Oops sorry Pharma. 

Missing You Already

We wish them well in their New Jobs

Research: Mixing statins with Interferons do not add up

Bhardwaj S, Coleman CI, Sobieraj DM.Efficacy of statins in combination with interferon therapy in multiple sclerosis: A meta-analysis. Am J Health Syst Pharm. 2012;69:1494-9. PURPOSE: The efficacy of statins in combination with interferon therapy in patients with multiple sclerosis (MS) is reviewed. METHODS: A systematic literature search was conducted through September 2011 to identify...

Research: time to relapse – a new outcome for RR trials

Epub: Sormani et al. Time to first relapse as an endpoint in multiple sclerosis clinical trials. Mult Scler. 2012. BACKGROUND: The increasing number of effective therapies to treat MS raises ethical concerns for the use of placebo in clinical trials, suggesting that new clinical trial design strategies are needed.   OBJECTIVES: To evaluate time to first relapse as an endpoint for MS clinical...

Research: Clinical Improvement after Venoplasty of CCSVI.

Epub: Hubbard D et al. Clinical Improvement after Extracranial Venoplasty in Multiple Sclerosis. Journal of Vascular and Interventional Radiology Epub online 28 August 2012.  Purpose: This study proposed to prospectively evaluate safety and clinical changes in outpatient endovascular treatment in patients with multiple sclerosis (MS) and chronic cerebrospinal venous insufficiency...

Unrelated Blogger Comments August

Sometimes you want to say something that is unrelated to the threads. This is a spot for you . “If you are a MSer at the Royal London Hospital please sign-up for our cognition study!” We may be slow at answering this Month  35 comments: AnonymousFriday, August 17, 2012 2:23:00 PM Alemtuzumab will no longer be sold in the UK I guess it will return at a much higher price when...

Research: Further evidence that Neurofilaments are a useful biomarker to detect damage

Khalil M et al. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2012 Aug. [Epub ahead of print] BACKGROUND: Axonal damage is considered a major cause of disability in multiple sclerosis (MS) and may start early in the disease. Specific biomarkers for this process are of great interest.  OBJECTIVE: To study if cerebrospinal fluid...

Research: sativex can alleviate spasticity in mice

Hilliard A, Stott C, Wright S, Guy G, Pryce G, Al-Izki S, Bolton C, Giovannoni G. Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis. ISRN Neurol. 2012;2012:802649. Epub 2012 Aug 7. This study investigated the anti-spasticity potential of Sativex in mice...


The 14th paralympics start in London today and this week many people will see wheelchair users (and blade runners, blind, deaf and walking enabled etc.) in a whole new light.


Best of Luck to Everyone

What do you expect from an effective DMT in progressive MS?

In clinic yesterday I was discussing the natalizumab SPMS trial with a SPMSer. It dawned on the MSer, after some discussion, that even if the trial was positive and they were randomised to active agent they would probably not notice any discernible effects at a personal or individual level. The reason for this is that we, the clinicians, don’t expect an effective drug for progressive MS to stop...



Recent Posts

Recent Comments